Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Recent News

Modeling Renal Injury in Multiple Myeloma
Challenges in Precision Medicine Strategies in Multiple Myeloma
Perlmutter Cancer Center Receives Anonymous Gift of $75 Million for New Blood Cancer Center
Does Intensive Therapy Improve Survival in Patients With Multiple Myeloma?
Daratumumab Split-Dosing Regimen for Multiple Myeloma Approved by the FDA
Researchers Launch Study of Precursor Conditions of Multiple Myeloma
African Ancestry and Genetic Alterations Leading to Multiple Myeloma
European Commission Approves Split-Dose of Daratumumab in Multiple Myeloma
Quadruplet Versus Triplet Therapy for Multiple Myeloma
Studying Heterogeneity in Myeloma via Single-Cell RNA Sequencing
Early Results of Phase I Study of CAR T-Cell Therapy in Multiple Myeloma
Novel Four-Drug Combination Therapy for Newly Diagnosed Multiple Myeloma
First-in-Class Agent Targets NF-kB Signaling in Multiple Myeloma
Venetoclax Combination Therapy for Resistant Multiple Myeloma
ASH 2018: First-Line Combination Regimens in Transplant-Ineligible Patients With Myeloma
ASH 2018: Novel Agent for Resistant Multiple Myeloma Under Study
ASH 2018: Is Urine Immunofixation Necessary to Define Complete Remission in Myeloma
ASH 2018: Frailty-Adjusted Treatment Approach for Elderly Patients With Myeloma
ASH 2018: Ixazomib Maintenance After Transplantation in Newly Diagnosed Multiple Myeloma
ASH 2018: Double vs. Single Autologous Transplantation in Newly Diagnosed Myeloma
ASH 2018: Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
ASH 2018: Transplant Versus Continuous Lenalidomide-Based Therapy for Relapsed Multiple Myeloma
Myeloma Crowd Launches Free Online Resource for Patients With Multiple Myeloma
FDA Grants Regenerative Medicine Advanced Therapy Designation to CAR T-Cell Therapy
ESMO 2018: Adding Liposomal Doxorubicin to Standard First-Line Therapy in Multiple Myeloma
FDA Grants Priority Review to Ruxolitinib for Acute Graft-Versus-Host-Disease
ASTRO 2018: Impact of Dosage on Re-irradiation Rates in Multiple Myeloma
FDA Approves Immunotherapy Combination in Relapsed or Refractory Multiple Myeloma
Rare Case of CML After Stem Cell Transplantation in Patient With Multiple Myeloma
Phase I Study of New Triplet Therapy for Resistant Myeloma
FDA Offers Draft Guidance on Use of MRD in Hematologic Malignancies
Investigational Therapy for Myeloma, STRO-001, Granted Orphan Drug Designation by FDA
ESMO 2018: Strategy for Offsetting Lenalidomide-Induced Rash in Multiple Myeloma
FDA Grants Priority Review to Selinexor for Pentarefractory Multiple Myeloma
Can Simple Blood Tests Diagnose Early Multiple Myeloma?
FDA Permits Use of Next-Generation Sequencing–Based Test in Multiple Myeloma
Quality Care Symposium: Steady Improvement in Survival in Multiple Myeloma
FDA Approves Once-Weekly Carfilzomib With Dexamethasone in Resistant Multiple Myeloma
Novel Approach to Restoring Beneficial Gut Bacteria After HCT
Can Artificial Intelligence Platform Optimize Combination Therapy for Multiple Myeloma?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.